# MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

> **NCT05438563** · NA · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 100 (estimated)

## Conditions studied

- Prostate Carcinoma
- Stage I Prostate Cancer AJCC v8
- Stage II Prostate Cancer AJCC v8

## Interventions

- **PROCEDURE:** MRI-Guided Transurethral Ultrasound Ablation
- **OTHER:** Questionnaire Administration
- **PROCEDURE:** Digital Rectal Examination
- **PROCEDURE:** Cystoscopy
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** PSMA PET Scan
- **PROCEDURE:** Multiparametric Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT05438563
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-06
- **Primary completion:** 2027-03-07
- **Final completion:** 2027-03-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05438563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05438563, "MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05438563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*